Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer

[1]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[2]  O. Meyuhas,et al.  Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. , 2006, Trends in biochemical sciences.

[3]  Rony Seger,et al.  The ERK Cascade: Distinct Functions within Various Subcellular Organelles. , 2011, Genes & cancer.

[4]  A. Kazlauskas,et al.  The PDGF receptor alpha subunit activates p21ras and triggers DNA synthesis without interacting with rasGAP. , 1994, Oncogene.

[5]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[6]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[7]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[8]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[9]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[10]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[11]  R. Neve,et al.  A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation. , 2013, The Biochemical journal.

[12]  C. Der,et al.  Inhibition of Ras for cancer treatment: the search continues. , 2011, Future medicinal chemistry.

[13]  Joel S. Parker,et al.  Adjustment of systematic microarray data biases , 2004, Bioinform..

[14]  Hyun Cheol Chung,et al.  Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer , 2009, PLoS genetics.

[15]  Julian Downward,et al.  Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. , 2013, Cancer discovery.

[16]  D. Hayes,et al.  HIF2α cooperates with RAS to promote lung tumorigenesis in mice (Journal of Clinical Investigation (2009) 119, (2160-2170) doi:101172/JCI38443) , 2009 .

[17]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[18]  Larry Norton,et al.  Latent bone metastasis in breast cancer tied to Src-dependent survival signals. , 2009, Cancer cell.

[19]  D. Hayes,et al.  HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. , 2009, The Journal of clinical investigation.

[20]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[21]  T. Barrette,et al.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.

[22]  L. Benesova,et al.  Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplification. , 2011, Cancer genomics & proteomics.

[23]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[24]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[25]  John D Minna,et al.  Molecular biology of lung cancer: clinical implications. , 2002, Clinics in chest medicine.

[26]  M. Rooney,et al.  Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[28]  J. Blenis,et al.  RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation* , 2007, Journal of Biological Chemistry.

[29]  Edward C Stites,et al.  Network Analysis of Oncogenic Ras Activation in Cancer , 2007, Science.

[30]  C. Der,et al.  Ras history , 2010, Small GTPases.

[31]  Fabio Puglisi,et al.  Gene expression profiling in breast cancer: a clinical perspective. , 2013, Breast.

[32]  H. Burstein,et al.  The distinctive nature of HER2-positive breast cancers. , 2005, The New England journal of medicine.

[33]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[34]  Lee S. Rosen,et al.  Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review , 2010, The oncologist.

[35]  H. Huynh,et al.  Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  竹澤 健.  Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells , 2010 .

[37]  Frank McCormick,et al.  EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma , 2009, Science Signaling.

[38]  Wei-Min Liu,et al.  Robust estimators for expression analysis , 2002, Bioinform..

[39]  Igor Jurisica,et al.  Prognostic gene signatures for non-small-cell lung cancer , 2009, Proceedings of the National Academy of Sciences.

[40]  Yi-long Wu,et al.  KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy , 2013, Annals of Surgical Oncology.

[41]  Channing J Der,et al.  Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? , 2004, Trends in cell biology.

[42]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[43]  W. Pao,et al.  KRAS mutations in non-small cell lung cancer. , 2009, Proceedings of the American Thoracic Society.

[44]  Robert Pirker,et al.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.

[45]  Lucio Crinò,et al.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.

[46]  F. McCormick,et al.  Therapeutic strategies for targeting ras proteins. , 2011, Genes & cancer.

[47]  D. Fabbro,et al.  In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.

[48]  T. Sakai,et al.  Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2 , 2012, Oncotarget.

[49]  S Sommer,et al.  Estrogen Receptor and Breast Cancer , 2001, Cancer Drug Discovery and Development.

[50]  Kwang-Hyun Cho,et al.  Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway , 2009, Journal of Cell Science.

[51]  K. O'Byrne,et al.  Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. , 2011, The Lancet. Oncology.

[52]  Nils Blüthgen,et al.  Strong negative feedback from Erk to Raf confers robustness to MAPK signalling , 2011, Molecular systems biology.

[53]  C. Berking,et al.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.

[54]  M. Kuwano,et al.  Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs , 2006, Clinical Cancer Research.

[55]  Giorgio Scita,et al.  Mechanisms through which Sos-1 coordinates the activation of Ras and Rac , 2002, The Journal of cell biology.

[56]  Bertram Klinger,et al.  Supplementary Materials for : Network quantification of EGFR signaling unveils potential for targeted combination therapy , 2022 .

[57]  T. Stinchcombe,et al.  KRAS mutation: should we test for it, and does it matter? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  C. Comin,et al.  From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy. , 2011, Tumori.

[59]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[60]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[61]  Jeffrey T. Chang,et al.  A genomic strategy to elucidate modules of oncogenic pathway signaling networks. , 2009, Molecular cell.

[62]  Ming-Sound Tsao,et al.  K-ras mutations in non-small-cell lung carcinoma: a review. , 2006, Clinical lung cancer.

[63]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[65]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[66]  Jie Yang,et al.  Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. , 2013, Lung cancer.

[67]  藤倉雄二,et al.  わが国における成人市中肺炎原因微生物についてのsystematic review/meta‐analysis , 2016 .

[68]  Julian Downward,et al.  Cancer biology: Signatures guide drug choice , 2006, Nature.

[69]  H. Ikeuchi,et al.  Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. , 2011, European journal of cancer.

[70]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[71]  M. Socinski,et al.  Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  P. Tooley,et al.  Food and drugs , 1971 .

[73]  M. Ladanyi,et al.  Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas , 2013, Cancer.

[74]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[75]  A. Balmain,et al.  Interactions Between Wildtype and Mutant Ras Genes in Lung and Skin Carcinogenesis , 2012, Oncogene.

[76]  L. Tanoue,et al.  Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .

[77]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.